Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 76
Anti-IL 21 in combination with liraglutide is an alternative
approach for the treatment of type 1 diabetes
Phase 2 trial design
Anti-IL-21 + liraglutide 1.8 mg
Placebo + liraglutide 1.8 mg
type 1 diabetes¹
Anti-IL-21 + placebo
304 newly
diagnosed
people with
Placebo + placebo
+
Week 0
54
80
Dosing
Observation
Rationale for Anti-IL 21 and liraglutide
combination product for T1D
Anti-IL 21 plays an important role in autoimmunity with
potential effect on immune disorder
Effector cells (T and B lymphocytes and natural killer cells)
Pro-inflammatory cytokines
Autoantibodies
Chemokines
Matrix metalloproteinase (MMPs)
GLP-1 receptor agonist may promote beta-cell recovery
Decrease beta-cell stress/apoptosis
Stimulate beta-cell neogenesis
Expansion of beta-cell mass in rodent models
1 Inclusion criteria: Subjects diagnosed as type 1 diabetes for not more than 12 weeks prior to
randomisation; age 18-45 (both inclusive)
Note: If liraglutide 1.8 mg is not tolerated 1.2 mg is administered. ANTI-IL: interleukin
T1D: Type 1 diabetes; MOA: Mode of action
changing
diabetes®
novo nordiskView entire presentation